Dosing & administration for migraine

For your patients with migraine,

Emgality comes in an easy-to-use pen for self-administration that can fit into your patient’s life^1,2

^aPatient- and caregiver-rated experiences with the pen were assessed in an open-label, 12-month study. A total of 84 patients who received once-monthly injections of Emgality 120 mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use and the respondents’ confidence in their ability to use the device.³

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Recommended dosing with no titration required^1a

Month 1:

Initial loading dose of 240 mg
(two 120 mg injections)

Subsequent months:

One 120 mg injection per month

^aThe Emgality Pen needle is 27 gauge x 1/2 inch.⁴

CGRP=calcitonin gene-related peptide.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

How to administer Emgality

Preparation⁷

• Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
• Choose an area for injection (abdomen or thigh if self-injecting and buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within an area) each month
• Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: The 3 key administration steps⁷

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

Telephonic injection training and an injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548).

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Watch how to use the Emgality Pen

This video is hosted on YouTube, a platform which Lilly USA, LLC does not control, influence, or endorse. Lilly is not responsible for any content on this third-party site, including the privacy policy.

Click "continue" to watch this video hosted on YouTube.

Continue

Prescribing Information

Patient Information

Instructions for Use

If you or your patients have any questions about Emgality, call 1-833-EMGALITY (1-833-364-2548) to talk to a healthcare provider.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

How to locate and prescribe Emgality using the Electronic Media Record (EMR) system

Search for “Emgality”

In the EMR system, select the formulation for your patient’s diagnosis¹:

Recommended Dosing	National Drug Code (NDC)	Pen or Syringe Quantity
Recommended Dosing: Emgality Pen 120 mg/mL SC injection	National Drug Code (NDC): NDC 0002-1436-11	Pen or Syringe Quantity: Qty: 1 per box
Recommended Dosing: Emgality Syringe 120 mg/mL SC injection	National Drug Code (NDC): NDC 0002-2377-11	Pen or Syringe Quantity: Qty: 1 per box

SC=subcutaneous.

Prescribe the appropriate dose for your patient:

Emgality 120 mg for migraine

Loading Dose

(Use only if the patient does not begin treatment with a Loading Dose Kit [sample]^a in the office)

Dispense: 2 pens or syringes at once with 0 refills

Maintenance Dose

(Use for all patients with migraine)

Dispense: 1 pen or syringe once monthly with 10 refills

^aLoading Dose Kits (samples) are intended to establish tolerability and efficacy for a patient.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Discover how eligible patients can get Emgality for as little as $0 for up to 12 months^a. View savings cards

Terms and Conditions:
^aOffer good until 12/31/2022 for up to 12 months of Emgality. Patients that have commercial drug insurance but do not have coverage for Emgality may be able to pay as little as $0 for their first fill of Emgality. Patients that have commercial drug insurance and have coverage for Emgality may be able to pay as little as $0 per fill. Offer subject to a monthly cap and a separate annual cap. Monthly and annual caps are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or whose prescription claims for Emgality are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0013. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0020. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0060. 5. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019. 6. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019. 7. Emgality [Autoinjector Instructions for Use]. Indianapolis, IN: Lilly USA, LLC.